SCHEMBL4963408

SCHEMBL4963408

O=C1c2ncc3c(c(COCCOc4ccccc4)cn3Cc3ccc(F)cc3)c2CCN1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARD Q03181 3/20 0.37
▸ LMNA P02545 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ NCOA3 Q9Y6Q9 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.34
▸ HTT P42858 1/20 0.34
▸ PPARG P37231 2/20 0.33
▸ PPARA Q07869 2/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ EGFR P00533 1/20 0.33
▸ IGF1R P08069 1/20 0.33
▸ FLT4 P35916 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CXCR3 P49682 1/20 0.32
▸ PRKAA2 P54646 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4964610 0.94 SMN1; SMN2 (0.41) PPARDLMNASMN1; SMN2L3MBTL1NCOA3
SCHEMBL4962798 0.89 PKM (0.34) LMNASMN1; SMN2L3MBTL1NCOA3ALDH1A1
SCHEMBL4966779 0.89 PKM (0.37) PPARDLMNASMN1; SMN2L3MBTL1NCOA3
SCHEMBL4962397 0.89 PKM (0.35) PPARDLMNASMN1; SMN2L3MBTL1NCOA3
SCHEMBL4965989 0.88 SMN1; SMN2 (0.36) LMNASMN1; SMN2L3MBTL1NCOA3ALDH1A1
Hydrochloric Acid SCHEMBL5420984 0.88 SMN1; SMN2 (0.35) LMNASMN1; SMN2L3MBTL1NCOA3ALDH1A1
SCHEMBL4962824 0.87 PKM (0.33) LMNASMN1; SMN2L3MBTL1NCOA3ALDH1A1
SCHEMBL4964902 0.87 PKM (0.34) PPARDLMNASMN1; SMN2L3MBTL1NCOA3
SCHEMBL4966404 0.87 PKM (0.33) LMNASMN1; SMN2L3MBTL1NCOA3ALDH1A1
SCHEMBL4962937 0.87 PKM (0.35) PPARDLMNASMN1; SMN2L3MBTL1NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934220-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME Pfizer Products Incorporated (US) 2008-06-25 — — EP disclosed
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC. 2007-05-03 — — US disclosed
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC. 2007-05-03 — — US disclosed
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC. 2007-05-03 — — US disclosed
WO-2007042883-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER PRODUCTS INC. (US) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME IMPDH1, INTS9, TYMP PPARD 3557/4885LMNA 3259/4885SMN1; SMN2 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback